ENXTPA:IVA

Stock Analysis Report

Executive Summary

Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases.

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

+ 1 more risk


Snowflake Analysis

Mediocre balance sheet and overvalued.

Share Price & News

How has Inventiva's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IVA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

11.6%

IVA

3.4%

FR Biotechs

1.2%

FR Market


1 Year Return

-48.6%

IVA

-29.7%

FR Biotechs

20.8%

FR Market

Return vs Industry: IVA underperformed the French Biotechs industry which returned -29.7% over the past year.

Return vs Market: IVA underperformed the French Market which returned 20.8% over the past year.


Shareholder returns

IVAIndustryMarket
7 Day11.6%3.4%1.2%
30 Day16.0%4.4%-0.7%
90 Day61.9%-5.5%3.6%
1 Year-48.6%-48.6%-29.6%-29.7%25.1%20.8%
3 Yearn/a-58.8%-58.8%41.1%27.4%
5 Yearn/a-59.4%-60.0%77.1%50.8%

Price Volatility Vs. Market

How volatile is Inventiva's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Inventiva undervalued compared to its fair value and its price relative to the market?

1.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IVA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IVA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IVA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IVA is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IVA is good value based on its PB Ratio (1.8x) compared to the FR Biotechs industry average (2x).


Next Steps

Future Growth

How is Inventiva forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

6.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IVA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IVA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IVA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IVA's revenue is expected to decline over the next 3 years (-19.4% per year).

High Growth Revenue: IVA's revenue is forecast to decline over the next 3 years (-19.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IVA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Inventiva performed over the past 5 years?

-44.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IVA is currently unprofitable.

Growing Profit Margin: IVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IVA is unprofitable, and losses have increased over the past 5 years at a rate of -44.1% per year.

Accelerating Growth: Unable to compare IVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: IVA has a negative Return on Equity (-91.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Inventiva's financial position?


Financial Position Analysis

Short Term Liabilities: IVA's short term assets (€52.4M) exceed its short term liabilities (€16.5M).

Long Term Liabilities: IVA's short term assets (€52.4M) exceed its long term liabilities (€3.0M).


Debt to Equity History and Analysis

Debt Level: IVA's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: IVA's debt to equity ratio has increased from 0.2% to 0.4% over the past 5 years.


Balance Sheet

Inventory Level: IVA has a low level of unsold assets or inventory.

Debt Coverage by Assets: IVA's debt is covered by short term assets (assets are 340.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IVA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IVA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -36.3% each year


Next Steps

Dividend

What is Inventiva's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%4.6%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IVA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IVA's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

What is the CEO of Inventiva's salary, the management and board of directors tenure and is there insider trading?

7.3yrs

Average management tenure


CEO

Frederic Cren 0

8.9yrs

Tenure

€375,840

Compensation

Mr. Frederic Cren is a Co-Founder of Inventiva S.A. since and also serves as its Chief Executive Officer since 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 2016 and also serves as its Direc ...


CEO Compensation Analysis

Compensation vs Market: Frederic's total compensation ($USD417.00K) is above average for companies of similar size in the French market ($USD320.27K).

Compensation vs Earnings: Frederic's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

7.3yrs

Average Tenure

Experienced Management: IVA's management team is seasoned and experienced (7.3 years average tenure).


Board Age and Tenure

1.6yrs

Average Tenure

55yo

Average Age

Experienced Board: IVA's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.9%.


Management Team

  • Marie-Paul Richard (64yo)

    Chief Medical Officer

    • Tenure: 1.2yrs
  • Kristina Meyer

    Head of Business Development

    • Tenure: 0yrs
  • Pierre Broqua

    Co-Founder

    • Tenure: 3.6yrs
    • Compensation: €262.58k
  • Frederic Cren

    Co-Founder

    • Tenure: 8.9yrs
    • Compensation: €375.84k
  • Jean Volatier

    Chief Financial Officer

    • Tenure: 7.3yrs
  • Nathalie Harroy

    Head of Human Resources

    • Tenure: 0yrs
  • Olivier Lacombe

    Head of Pharmacokinetics

    • Tenure: 0yrs
  • Christian Montalbetti

    Head of Chemistry

    • Tenure: 0yrs
  • Irena Konstantinova

    Head of Biology & Pharmacology

    • Tenure: 0yrs
  • Nicolas Gueugnon

    Legal Director

    • Tenure: 0yrs

Board Members

  • Chris Buyse (55yo)

    Independent Director

    • Tenure: 0yrs
  • Annick Schwebig (68yo)

    Independent Director

    • Tenure: 0yrs
    • Compensation: €40.00k
  • Jean-Louis Junien

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: €30.00k
  • Lucy Lu (44yo)

    Independent Director

    • Tenure: 1.6yrs
    • Compensation: €15.00k
  • Pierre Broqua

    Co-Founder

    • Tenure: 3.6yrs
    • Compensation: €262.58k
  • Frederic Cren

    Co-Founder

    • Tenure: 8.9yrs
    • Compensation: €375.84k
  • Nawal Ouzren

    Independent Director

    • Tenure: 0.9yrs
  • Heinz Maeusli

    Independent Director

    • Tenure: 0.9yrs
  • Sven Francque

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Manal Abdelmalek

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Inventiva S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inventiva S.A.
  • Ticker: IVA
  • Exchange: ENXTPA
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €86.760m
  • Shares outstanding: 26.53m
  • Website: https://www.inventivapharma.com

Number of Employees


Location

  • Inventiva S.A.
  • 50 rue de Dijon
  • Daix
  • Burgundy
  • 21121
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IVAENXTPA (Euronext Paris)YesOrdinary SharesFREURFeb 2017
0RNKLSE (London Stock Exchange)YesOrdinary SharesGBEURFeb 2017
IVEV.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2017

Biography

Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to tre ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/10 22:59
End of Day Share Price2019/12/10 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.